Back to the Top
We are trying to measure Carboplatin and Cisplatin through HPLC and a=20
fluorometric detector. We have tried to combine these citostatics=20
with quinolein molecules to make these citostatics detectable, but it=20
hasn=B4t given any succesful outcome. Does anybody has experience at=20
Cisplatin or Carboplatin detection after HPLC separation ? .
Thank you in advance for any information provided
Jaime C=E1rcel Trullols , Depto de Farmacia y Tecnolog=EDa farmac=E9utica ,=
=20
Facultad de Farmacia , Universidad de Valencia , Espa=F1a .
Back to the Top
[Three replies - db]
Reply-To: "Stephen Duffull"
From: "Stephen Duffull"
To:
Subject: Re: PharmPK About Carboplatin and Cisplatin
Date: Thu, 9 Sep 1999 09:20:49 +0100
X-Priority: 3
Hi Jaime
I Have no experience in detecting cisplatin by HPLC but have
done a little work on carboplatin. I used reversed phase
HPLC with UV detection at an absorbance of 190nm. The
inter-run CV at all concs of the standard curve
[range=3D2.5-50 mg/L] was <7%. Please get back to me if you
want further details.
Regards
Steve
Stephen Duffull
School of Pharmacy
University of Manchester
Manchester, M13 9PL, UK
Ph +44 161 275 2355
Fax +44 161 275 2396
---
Date: Thu, 09 Sep 1999 12:56:18 +0200
Reply-To: ckloft.-at-.zedat.fu-berlin.de
From: "Dr. Charlotte Kloft"
To: PharmPK.-at-.boomer.org
Subject: Re: PharmPK About Carboplatin and Cisplatin
Some references of HPLC assays that might help you:
RP-HPLC:
=2E Riley C.M., Sternson L.A., Repta A.J. Anal. Biochem. 124: 167, 1982
. Cheung Y.-W., Cradock J.C., Vishnuvajjala B.R., Flora P.K.=20
Am. J. Hosp. Pharm. 44: 124, 1987
UV detection:
=2E Duncan G.F., Faulkner H.C., Farmen R.H., Pittman K.A. J.=20
Pharm. Sci. 77: 273, 1988
. Gaver R.C., Deeb G. Cancer Chemother. Pharmacol. 16: 201, 1986
=2E Parsons P.J., Morrision P.F., LeRoy A.F. J. Chromatogr. 385: 323, 1987
Ion exchange coupled columns plus derivatisation: .
Anderson A., Ehrsson H. J. Chromatogr. B 652: 203, 1994
. Andrews P.A., Wung W.E., Howell S.B. Anal. Biochem. 143: 46, 1984
HPLC-MS
=2E Burns R.B., Burton R.W., Albon S.P., Embree L. J. Pharm.=20
Biomed. Anal. 14: 367, 1996
. Zhao Z., Tepperman K., Dorsey J.G., Elder R.C. J. Chromatogr.=20
Biomed. Appl. 615: 83, 1993
. Cairns, W.R.L., Ebdon L., Hill S.J. Anal. Prog. 31: 295, 1994
In genereal, HPLC assays often do not allow the simultaneous=20
determination of all platinum species that may be formed (active=20
hydrolysis and other reaction products) but -depending on the=20
question you want to investigate- provide a more specificed picture=20
than e.g. AAS assays.
best regards,
Charlotte Kloft
********************************************
Dr. Charlotte Kloft
Freie Universit=E4t Berlin
Institut f=FCr Pharmazie
Abt. Klinische Pharmazie
Kelchstr. 31
D-12169 Berlin
Germany
Fon/Fax: +49 (0) 30 77 00 04 28
EMail: ckloft.-a-.zedat.fu-berlin.de
---
From: "Fackler, Paul (CNTCPI1)"
To: PharmPK.aaa.boomer.org
Subject: RE: PharmPK About Carboplatin and Cisplatin
Date: Thu, 9 Sep 1999 09:42:42 -0400
A long time ago I used to analyze carboplatin by using HPLC with atomic
absorption (AA) detection. You can match the mobile phase flow rate to the
aspirator rate on the AA and detect platinum in the HPLC flow. Using a strip
chart recorder, or data acquisition system, you get chromatograms of
platinum containing peaks. Please contact me directly if you have any
questions.
Paul Fackler
Copley Pharmaceutical
facklp.at.copleynet.com
Back to the Top
Much more easier and efficient to just use ICP-MS or AA as the
serum Pt profile is almost superimposed with serum carboplatin
levels.
Also, be aware that some common mobile phase components can
complex with Pt-containing molecules.
Cheers,
BC
Bruce CHARLES, PhD
Senior Lecturer
Director, The Australian Centre for Paediatric Pharmacokinetics
University of Queensland, School of Pharmacy, QLD 4072
Australia
+61 7 336 53194 (TEL)
+61 7 336 51688 (FAX)
bruce.aaa.pharmacy.uq.edu.au
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)